This workshop will explore the need for early detection and identification of clinically important organisms, including the most prevalent ESKAPE pathogens, to provide earlier targeted therapy for the most critically compromised patients.

Join us as we discuss the evaluation data of the FDA-cleared T2Bacteria® and T2Candida® Panels in the clinical lab and how it can impact patient management. Learn how early detection of the most serious bacterial and fungal pathogens in 3 to 5 hours direct from whole blood—and without the wait for blood culture—can improve on antibiotic empiric therapy protocols and achieve targeted therapy faster.  T2Direct Diagnostic panels are run on the T2Dx® Instrument with validated sensitivity of 91 to 96% and specificity of 98 to 99% which enable clinicians to  the potential to improve patient outcomes.